PCSK9 Inhibitors…Closer to Approval?

This week the FDA Endocrinologic and Metabolic Drugs Advisory Committee will discuss the safety and efficacy of two PCSK9 inhibitor drugs (Praluent and Repatha) and may recommend approval of these drugs to lower cholesterol. Recently published research in NEJM showed reduced cardiovascular outcomes with these inhibitors and has sparked guarded optimism from the medical community. UT Southwestern cardiologist, Dr. Amit Khera, was recently quoted in Medscape regarding these powerful cholesterol lowering medications, “If you’re a cardiologist, you must not have a pulse if you’re not excited.” Click on the link below to read more from The Washington Post!

Could these New Cholesterol Drugs Save Many Americans from Heart Attacks?

UPDATE!

The FDA panel today¬†recommended approval of the cholesterol drug, alirocumab, in a 13-3 vote. Click on the link below to read a summary from today’s developments from The New York Times.

Federal Panel Recommends Approving New Cholesterol Drug